Develop Successful Combination Strategies Validate Novel Pathways Identify Clinically Relevant Biomarkers

Transcription

1 2nd Annual Boston Develop Successful Combination Strategies Validate Novel Pathways Identify Clinically Relevant Biomarkers 33 Expert Speakers Including: Roy Baynes SVP, Global Clinical Merck Michael Giordano SVP, Head of Bristol-Myers Squibb Tony Ho, Global Medicine Leader Durvalumab (MEDI4736) AstraZeneca Philip Gotwals Executive Director, Exploratory Novartis Bill Grossman Group Medical Director, Cancer Immunotherapy Franchise Genentech Axel Hoos VP, Oncology R&D GSK Mary-Lynne Hedley President and COO TESARO Ruslan Novosiadly Senior Research Advisor, Biomarkers Eli Lilly Jean-Marie Cuillerot VP, EMD Serono Partners: Researched & Developed By: Tel: Immune Checkpoint

2 Welcome to ICI Boston Optimize The Success Of Your Programs ICI Boston exists to address the biggest challenges faced in developing immune modulators. The last 12 months have seen an explosion of data, with a renewed emphasis on inhibitory and agonistic pathways, new disease indications and combination potential. But, despite the industry making rapid strides, there is still work to do to replicate the successes of nivolumab and pembrolizumab. Working with the likes of BMS, Merck, AstraZeneca and Genentech, this year s agenda focuses on novel pathway validation, biomarker identification and clinical combination strategies. Gain the latest clinical insights through keynote talks from Roy Baynes and Michael Giordano as well as previewing innovative work being carried out by Incyte, Tesaro, GITR Inc. and others. Accelerate your checkpoint programs by: Hearing about discovery and validation of pathway biologies beyond PD-1 Reviewing immuno-oncology combinations that deliver more robust and durable responses Learning about novel biomarkers for patient stratification Appreciating the commercial strategy of the current marketed products Debating clinical strategies to support the rapid generation of trial data Assessing new preclinical models that effectively recapitulate the human immune system and improve predictability into the clinic Listening to novel research on the TME, immune ecosystem and how these influence efficacy With 33 expert speakers there is a huge amount to learn over the 3 days. Take a look at the agenda to see what insights will be presented. Hear What Previous ICI Attendees Have To Say: Excellent meeting. Great opportunity for discussions between academia, small start ups, large pharma and regulatory authorities. All of the speakers were very forthcoming about their developing pipelines and emerging therapeutics. What Makes ICI Boston A Must Attend? In March 2015, 150 experts in the immune checkpoint field came together and experienced the success of the first industry-led conference specifically focused on immune checkpoint modulation. Building on this success, ICI Boston 2016 represents the culmination of intensive research into the industry, which has resulted in the most comprehensive and detailed agenda of any conference in the area. ICI Boston is the only conference that will allow you to rub shoulders with the market leading pharmaceutical companies. Gain valuable insights into the future of the field through specifically selected case studies from some of the most innovative small companies and pioneering academics in the immune checkpoint inhibitors space. Engage with over 200 researchers, all focused on accelerating the development of the next generation of checkpoint drugs.

3 Speakers Roy Baynes SVP, Global Clinical Merck Tehila Ben-Moshe CEO, VP R&D ccam Biotherapeutics Gary Bembridge Director, Scientific Affairs, Immunology Abzena Dirk Brockstedt SVP, Research and Aduro Biotech Eustache Paramithiotis VP, Biomarker Discovery & Diagnostics Caprion Jean-Marie Cuillerot VP, EMD Serono Greg Dombal COO Halloran Consulting Group Andrew Ferguson Clinical Scientist TESARO Tara Gangadhar Assistant Professor, Abramson Cancer Center University of Pennsylvania Michael Giordano SVP, Head of Bristol-Myers Squibb Philip Gotwals Executive Director, Exploratory Novartis Bill Grossman Group Medical Director, Cancer Immunotherapy Franchise Genentech Fiona Harding Senior Principal Research Scientist Abbvie Mary-Lynne Hedley President and COO TESARO Henry Hepburne-Scott Director, Business Serametrix Tony Ho Global Medicine Leader Durvalumab (MEDI4736) AstraZeneca Axel Hoos VP, Oncology R&D GSK Jeff Hutchins VP, Preclinical Research Peregrine Pharmaceuticals Speaker to be confirmed The Jackson Laboratory David Kaufman, Executive Director, Translational Merck Francis Kern Senior Director, External Scientific Affairs Daiichi Sankyo Holly Koblish Associate Director Incyte Jason Luke Assistant Professor University of Chicago Walter Newman Director GITR Inc. Ruslan Novosiadly Senior Research Advisor, Biomarkers Eli Lilly Patrick Ott Clinical Director, Centre for Immuno- Oncology Dana-Farber Paul Rennert Founder and Principal SugarCone Biotech Consultants Naiyer Rizvi Director of Immunotherapeutics Columbia University Medical Center Eric Rubin VP, Global Clinical Oncology Merck Michael Seiler Associate Director, Product Management Taconic Chris Turner VP, Clinical Science Celldex Jennifer Wargo Associate Professor MD Anderson Cancer Centre Jon Wigginton SVP, Clinical MacroGenics This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics! AstraZeneca, ICI Europe Attendee

4 Conference Agenda, Day One Wednesday March Chair s Opening Remarks Capitalize on Future ICI Opportunities 8.30 Anti-PD-1 Antibody Holds the Promise of Being a Broad Spectrum Antineoplastic Therapy Investigating adaptive phase 1 and parsimonious screening phase 2 studies that have accelerated development Analyzing the breadth and depth of the PD-1 antibody addressable cancers Selecting the appropriate patients for monotherapy and for the exploration of novel approaches including combinations 9.00 Leaving PD-1 and CTLA-4 Monotherapy Behind? Discuss the Transitional Dynamics at Play in the ICI Space to Make Informed Decisions About Future Strategy To what extent does the future of ICIs lay primarily in combination therapy vs novel target discovery? Should ICI monotherapy be considered the primary treatment option ahead of combination therapy? How will the priorities of the ICI community evolve over the next 5 years? Mary-Lynne Hedley, President and COO, TESARO Roy Baynes, SVP, Global Clinical, Merck Axel Hoos, VP, Oncology R&D, GSK Speed Networking & Morning Refreshments Preclinical Stream Validate Novel Immuno-Modulatory Checkpoints Treating Cancer by Targeted Activation of the Immune System Discussing the role of checkpoint inhibitors in the context of a broader immuno-oncology strategy Outlining the status of the Novartis checkpoint pipeline Reviewing approaches to the discovery of novel CPIs Phil Gotwals, Executive Director,, Novartis Small Molecule Inhibition of Tumor Immune Suppression: IDO1 and Beyond Selective IDO1 inhibition modulates the immune microenvironment and impacts tumor growth in preclinical models Combinations of IDO1 inhibition and checkpoint blockade allow for increased efficacy in preclinical models and disease control in cancer patients Selective JAK and PI3Kδ inhibition could be alternative strategies to enhance immune responses to tumors and are worthy of clinical study Holly Koblish, Associate Director, Pharmacology, Incyte Tipping the Balance: the Potential of TIM-3 and LAG-3 Inhibition to Augment Immunotherapy Inhibitory vs stimulatory effects of TIM-3 and LAG-3 on innate and adaptive immune cells Expression of TIM-3 and LAG-3 in various tumor types Preclinical support for TIM-3 and LAG-3 expression in murine and ex vivo tumor models Do you always need PD-1/L1 blockade? Andrew Ferguson, Clinical Scientist, TESARO Clinical Stream Enhance Combination Strategies to Maximize Efficacy Critically Evaluate The Use of Multiple Checkpoint Inhibitors in Combination Build on the lessons learned from combining nivolumab and ipilimumab for the treatment of melanoma Examine multiple variables contributing to successful combination strategy, including dosing and treatment timing Use these insights to improve combination trial design Patrick Ott, Clinical Director, Centre for, Dana-Farber Next-Generation Biomarkers for the Era of Combination Cancer Immunotherapy Biomarker and companion diagnostic development in the pembrolizumab program Translational research and biomarker approaches to address combination approaches in immuno-oncology David Kaufman, Executive Director, Translational Immuno- Oncology, Merck Releasing the Brake: Enhancing Immunotherapy Through Rational Combinations with Checkpoint Inhibitors Understand the key principals governing logical immunooncology combination strategies Lessons learnt from combining the novel target B7-H3 with ipilimumab and pembrolizumab Insights into the most promising future combination strategies Jon Wigginton, SVP, Clinical, MacroGenics

5 12.30 Lunch & Networking 2.00 Preclinical Pharmacology of Murine and Human Anti-GITR Antibodies Combinations of multiple immune checkpoint-directed therapies will likely change the paradigm of cancer therapy Antibodies targeting GITR represent an exciting new class of immune checkpoint-directed therapies Preclinical data with anti-gitr mabs demonstrate unique immune activation and potential as oncologic therapies TRX 518 is a humanized anti-human GITR mab that is currently in the clinic. Based on the data to date, it will be evaluated in further single and combination therapy studies Walter Newman, Director, GITR Inc Enhancing the Power of Checkpoint Inhibition by Simultaneously Blocking Upstream and Downstream Targets: The Role of Phosphatidylserine (PS), a Novel, Global Immune Checkpoint Inhibiting PS using Bavituximab, a novel PS-signaling pathway inhibitor, blocks the immunosuppressive signal within the tumor microenvironment Assessing impact of immune stimulation through Fcγreceptor interaction on immune modulating cells Effects on multiple other immune effector cells will be presented Jeff Hutchins, VP, Preclinical Research, Peregrine Pharmaceuticals 2.30 Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Review toxicity profiles of checkpoint blockade and dual checkpoint blockade Monitoring and management of checkpoint blockade-associated toxicities Clinical perspectives on the challenges of immune toxicity management Differences in AE assessment and management during drug development in phase I/II versus phase III and implications/ expectations for assessing drug tolerability Tara Gangadhar, Assistant Professor, University of Pennsylvania 2.30 Discovery and Validation of the Next Generation of Immune Checkpoint Inhibitors Investigate strategies to validate novel checkpoint pathways and the potential of novel targets and combination with active immunization Impact on the future of the immune checkpoint inhibitor field Dirk Brockstedt, SVP, Research and, Aduro Biotech 3.00 Afternoon Refreshments & Networking Harness Clinically Relevant Tumor Models 3.30 Precision Research Models of Human Immune System and Metabolic Function: Applications in Oncology Drug Discovery Current state of immune system engraftment models The next generation hunog-exl which extends the mechanistic functionality of current systems Recent advances in immuno-oncology applications with immune system engrafted mice 4.00 Addressing Challenges Associated with Modeling Therapies in Immunocompetent Animal Models Considerations for selecting surrogate mabs for immuno-oncology studies Immunocompetent murine tumor models: Selection of models and interpretation of results Michael Seiler, Associate Director, Product Management, Taconic Fiona Harding, Senior Principal Research Scientist, Abbvie 4.30 Patient Derived Xenografts In Humanized (CD34+) NSG Mice Efficacy Testing Evaluate experiments engrafting PDX tumors into humanized (CD34+) NSG mice Critically review the treatment of these tumor bearing mice with both traditional SOC drugs & checkpoint inhibitors Overview of the differences in tumor growth rate, SOC response & immune modulation as a component of preclinical drug efficacy testing will be discussed 5.00 Chair s Closing Remarks Mary-Lynne Hedley, President and COO, TESARO

6 Conference Agenda, Day Two Thursday March Chair s Opening Remarks Jean-Marie Cuillerot, VP,, EMD Serono Improve Clinical Outcomes With Checkpoint Modulators 9.00 Jumping the Next Hurdle: Overcoming Challenges Inhibiting the Efficacy of Approved PD-1 and CTLA-4 Inhibitors Assessing strategies to extend therapeutic benefits to reach a larger proportion of patients Understanding the optimum timing of ICI administration in relapsing patients Michael Giordano, SVP, Head of, Bristol-Myers Squibb Discover the effects of PD-1 blockade on the tumour microenvironment Assessing the durability of response to PD-1 and CTLA-4 treatment 9.30 Lessons Learned from the of Durvalumab and Tremelimumab Discuss insights into the mechanisms of anti-pd-l1 /anti-ctla-4 therapeutics strategy for immune checkpoint combination studies Evaluate endpoints for immunotherapy trials Morning Refreshments & Networking Preclinical Stream Advance Understanding of the Immune Ecosystem Advances in In Vitro PBMC Assays to Measure Functionality of ICIs Preclinically More details to be disclosed shortly Gary Bembridge, Director, Scientific Affairs, Immunology, Abzena Utilizing the T Cell-Inflamed Tumor Microenvironment to Guide Immunotherapy for Melanoma and Human Solid Tumors Discuss the clinical implications of anti-ctla-4 and anti- PD-1 antibodies in sequence and combination for melanoma Utilize the T cell-inflamed tumor microenvironment as a more encompassing and clinically useful model for immunotherapy biomarker development compared with PD-L1 Develop rational molecular and immunological combinatorial strategies for melanoma and other solid tumors based on improved understanding of the TME Jason Luke, Assistant Professor, University of Chicago Tony Ho, Global Medicine Leader Durvalumab (MEDI4736), AstraZeneca Clinical Stream Investigate Clinical Strategies to Monitor Immune Responses and Adverse Events The Emergence of icscore TM as a Novel Immune-Based Approach for Monitoring Cancer Patients Cancer immunotherapies offer great promise but some patients fail to respond Immune-based biomarker assays can help predict clinical response to this emerging drug class Serametrix has developed icscore TM, an immune monitoring system designed for cancer patients Henry Hepburne-Scott, Director, Business, Serametrix Examining the Safety Profile of Checkpoint Inhibitors: Current Status and Lessons Learned Administration of checkpoint inhibitors may result in adverse events that are caused by the intrinsic mode of action of these drugs and are so called immune-related adverse events Immune-related adverse events patterns have been extensively described Their management (early detection and early management) has improved and has contributed to broaden their use as a monotherapy or in combination Jean-Marie Cuillerot, VP,, EMD Serono Extended Q&A with session speakers Direct Identification of Neo-Epitopes for Cancer Vaccines and Adoptive T-Cell Therapies Direct detection of peptides presented by MHC is the most physiologically relevant way to identify both modified and non-modified neo-epitopes associated with cancer Naturally presented peptides were characterized in a pilot study of surgically resected renal cell carcinoma Characteristics of overall peptide presentation as well as specific examples of cancer associated peptides will be presented Eustache Paramithiotis, VP, Biomarker Discovery & Diagnostics, Caprion Lunch & Networking

7 Identify Translational Biomarkers to Stratify Patient Populations 1.00 Predictive Biomarkers for Pembrolizumab Clinical utility of PD-L1 immunohistochemistry in identifying responders to pembrolizumab Beyond PD-L1 immunohistochemistry potential of RNA- and DNA-based assays to identify responders to pembrolizumab Eric Rubin, VP, Global Clinical Oncology, Merck 1.30 Biomarker Discovery In : From The Bench To The Bedside And Back Biomarker discovery paradigm in immuno-oncology a shift from hypothesis-testing to hypothesis-generation High-throughput, high-content molecular and immune profiling enables comprehensive biomarker evaluation Interrogation of mechanistic biomarkers provides insight into rational combinations in immuno-oncology Ruslan Novosiadly, Senior Research Advisor, Cancer Biology Biomarkers, Eli Lilly 2.00 Understanding the Dynamics and Heterogeneity of Responses to Immune Checkpoint Blockade: Opportunities to Enhance Responses Through Translational Research Significant advances have been made in cancer therapy via the use of immune checkpoint blockade, but responses are heterogeneous and are not always durable Current predictive biomarkers in pre-treatment tumor samples are not robust, and better biomarkers in tumor (and in blood) are critically needed Molecular and immune profiling in longitudinal samples from patients on immune checkpoint blockade to identify putative biomarkers that are highly predictive of response Identifying putative mechanisms of therapeutic resistance and novel means to enhance response to therapy Jennifer Wargo, Associate Professor, MD Anderson Cancer Center Investigate Clinical Strategies to Monitor Immune Responses and Adverse Events 1.00 Deconstructing the Atezolizumab Success Story: Gain Valuable Insights From the Trailblazing PD-L1 Inhibitor Discover the potential of atezolizumab monotherapy and combination therapy as a front-line treatment PD-L1 expression as a predictive biomarker: Insight into responder populations in atezolizumab trials Understand the rationale governing atezolizumab combination strategy Bill Grossman, Group Medical Director, Cancer Immunotherapy Franchise, Genentech 1.30 Inhibition of the Novel Immune Checkpoint CEACAM1 Enhances Anti-Tumor Immunological Activity CEACAM1 is expressed by T and NK cells upon activation, and expression is seen across multiple tumor types independently of PD-L1 expression Homophilic CEACAM1 interactions induce co-inhibitory signals to lymphocytes The first in class humanized anti-ceacam1 mab CM24 (MK- 6018) inhibits the immunosuppressive effect of CEACAM1, leading to enhanced cancel cell killing by T and NK cells Tehila Ben-Moshe, CEO, VP R&D, ccam Biotherapeutics 2.00 Augmenting the Potency of Checkpoint Blockade by Combinations of Multiple Immune Modulators at Selected Steps in Immune Activation Mechanism of action of varlilumab, a fully human monoclonal agonist antibody that targets CD27, to enhance immune activation Using the agonist antibody varlilumab in combination with checkpoint inhibitors to augment anti-tumor activity Targeting tumor-specific protein antigens to the DEC-205 receptor on dendritic cells Chris Turner, VP, Clinical Science, Celldex 2.30 Afternoon Refreshments & Networking Navigate the Commercial Landscape to Ensure Future Success 3.00 Remaining Competitive in a Rapidly Evolving Field: Strategies to Establish and Reinforce Market Share Learn from case studies detailing mutually beneficial partnerships in the ICI space Explore methods of successfully adapting to an expanding field 3.30 Cross-Industry Perspectives on the Future of ICIs How can past challenges be interrogated to develop successful future strategies? What are the most immediate challenges that need to be prioritized? What does the next 5-10 years hold for the field? 4.15 Chair s Closing Remarks Francis Kern, Senior Director, External Scientific Affairs, Daiichi Sankyo Panellists: Bill Grossman Genentech Patrick Ott Dana-Farber Jean-Marie Cuillerot, VP,, EMD Serono Tel: info@hansonwade.com

8 Workshops - Tuesday March 15 Pre Conference Workshop A 8.30am-11.30am Review of the Immune Checkpoint Inhibitors Landscape Building on the success of this workshop at last year s conference, this interactive discussion will provide a valuable overview of the current state of the field and evaluate some of the most exciting future industry trends in immunotherapy, with a particular focus on combinatorial therapies. In such a rapidly evolving field, the opportunity to learn about and discuss current and future strategies make this workshop a must-attend. Attendees will learn: From a comprehensive overview of the most innovative case studies in the field Lessons from the clinical development of immune checkpoint inhibitors What the next five years will hold for this rapidly evolving space Workshop leader Paul Rennert Founder and Principal SugarCone Biotech Consultants Back by popular demand! Pre Conference Workshop B 12.00pm-3.00pm Focus on Biomarkers: Identifying Companion Diagnostics to Predict the Relative Success Rate of Immune Checkpoint Blockade The development and utility of clinical biomarkers has emerged as one of the most pressing challenges facing the immune checkpoint inhibitor field. Through this workshop, gain an in-depth understanding of this crucial aspect and learn about the current progress and future of biomarker development in this space. Case studies will focus on the advantages and disadvantages of various biomarker strategies, with the aim of identifying the most promising biomarker programs in development. Additional factors affecting the sensitivity to checkpoint blockade therapy will be discussed, for example an insight into how the mutational and neoantigen landscape of the tumor can determine sensitivity to PD-1 blockade. Attendees will learn: Evaluate the true value of PD-L1 as a relevant biomarker Analyse key factors determining sensitivity to immune checkpoint modulation Investigate the clinical relevance of novel biomarkers across tumor types Workshop leader Naiyer Rizvi Director of Immunotherapeutics Columbia University Medical Center Pre Conference Workshop C 3.30pm-6.30pm Overcome the Regulatory Challenges Encountered in the of the Next Generation of Immune Checkpoint Inhibitors One of the most critical clinical considerations in the development of checkpoint inhibitors is identifying appropriate measures of clinical effect. The tools we use to measure success on a patient-by-patient level are essential for charting and staying a regulatory course. This workshop will assess the relevance of traditional endpoints in measuring the clinical success of compounds, and discuss how existing regulatory criteria need to adapt to accommodate the specific challenges involved in the clinical development of immune checkpoint inhibitors. Case studies will outline relevant regulatory cases in the wider immuno-oncology field and assess the lessons that can be taken from these examples. Attendees will learn: The relevance of some traditional endpoints in checkpoint inhibitor trials Insight from a regulatory perspective on the immune checkpoint inhibitors field How the regulatory landscape of the area may adapt in response to new innovations Workshop leader Greg Dombal COO Halloran Consulting Group Tel: info@hansonwade.com

9 Networking At ICI Boston Speed Networking Run like speed dating, this structured networking session will facilitate quick introductions with the majority of attendees. Use this time wisely to meet others in the immuno-oncology field and identify those you want to spend more time with. Interactive Panel Discussions Take part in interactive discussion sessions focused around specific, high priority issues. Query the experiences and observations of our senior level speaker panel. Uncover new ideas and insights to fast track your own research. Structured Networking Breaks In between the formal presentations the networking carries on. Use the multiple refreshment and lunch breaks to continue your discussions in an informal relaxed atmosphere. Perfect organization. Program well planned with sufficient time for networking BMS You ll Meet People From... 8% 15% 6% 5% 27% INDUSTRY BREAKDOWN 19% 20% Pharma Platform Technology Biotech CRO Academics Dx Others 17% 20% 18% SENIORITY BREAKDOWN 22% 23% C-Level VP Director Manager Scientist 23% *Based on 2015 attendance Companies Which Attend ICI Include: Quick Fire Figures companies hours of % attended last year networking End User Audience

10 Sponsors Program Partners Exhibitors Partner with Us The pace of development in is both astounding and somewhat frightening. Analysts predict the space to grow in the range of billions to tens of billions of dollars. This success is based on the impending procession of new drugs but much is needed to realize this potential. Do you have products and services that will help pharma and biotech secure the next wave of drug approvals? Are you looking to build awareness of your company s offering in this competitive arena? We help support organizations investing in IO to help them establish new partnerships and achieve their goals faster. Get in touch to find out how we could work together. Contact Jason Williams Commercial Director Tel: +44 (0) Jason.williams@hansonwade.com

11 Venue Venue: Just a stone s throw away from the Commons, this boutique hotel takes inspiration from the city s rich history while revelling in the unpredictable. Each space at Revere Hotel complements the next, allowing you to create your own unique and original Boston experience. Explore a completely new side of the city at this luxury hotel in Boston. Very well organised conference and very focused on topics that matter. Top speakers. The best conference in the field in my opinion. Glenmark Hotel name: Revere Hotel Boston Common 200 Stuart Street Boston MA United States Accommodation: Overnight accommodation is not included in the registration fee, however accommodation options will be sent out with your confirmation upon registering. Prices & Discounts Package Prices Platinum: Conference + 3 workshops Gold: Conference + 2 Workshop Silver: Conference + 1 workshop Bronze: Conference only Register and pay before January 29th 2016 Standard Pricing $4296 (save $500) $4496 (save $300) $3687 (save $400) $3897 (save $200) $3098 (save $300) $3298 (save $100) $2499 (save $200) $2699 Workshops (Each) $699 $699 Not-for-profit rates are available online for government, academic and charitable organisations. Team Discounts * 3+ Delegates: 10% Discount 4+ Delegates: 15% Discount 5+ Delegates: 20% Discount Attend ICI Boston To: *Please note: Team discounts are only valid when three or more delegates from one company book and pay at the same time. Early Bird discounts require payment at the time of registration (or prior to the cut-off date) to secure the applicable discount. All advertised discounts cannot be combined with any other offer. When you ve made your selections Secure Your Place Develop Successful Combination Strategies Validate Novel Pathways Identify Clinically Relevant Biomarkers You can register your place quickly and easily online. Visit: Contact us: If you require any further information on the event, or would like us to assist you in making your booking, please contact Hanson Wade via the contact details below. TERMS & CONDITIONS Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time. Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH Code: 6190 Tel: info@hansonwade.com